NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)

Opportunity snapshot. This Grants.gov announcement - NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) - is cataloged under number PA-27-101 and tied to CFDA assistance listing 93.233;93.242;93.273;93.307;93.313;93.350;93.351;93.393;93.394;93.395;93.837;93.838;93.839;93.840;93.847;93.853;93.855;93.859;93.865;93.866;93.867, posted by National Institutes of Health. Grants.gov currently shows the opportunity as open, first posted on May 28, 2026 and last updated on June 1, 2026. The funding category is Discretionary, delivered as a grant.

Award economics. The award range on file is Varies by applicant. Cost sharing or matching funds are required, meaning applicants must contribute a portion of the project budget from non-federal sources, factor this into your financial plan before drafting the proposal. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. Applications close on April 5, 2029 - roughly 966 days from today. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.